Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK
17 December 2000. Related: Conference reports.
2000
Treatment strategies in 2000: planning first-line (and therefore, second-line) therapy
17 December 2000. Related: Conference reports.
When should HAART be started?
17 December 2000. Related: Conference reports.
MDR resistance transmission increases in the UK
17 December 2000. Related: Conference reports, Drug resistance.
Interferon-gamma treatment in azole-resistant oropharyngeal candidiasis
17 December 2000. Related: Conference reports, Coinfections and complications.
Further reports of avascular necrosis (AVN) and changes in bone mineral density (BMD)
17 December 2000. Related: Conference reports, Side effects.
Clinical issues arising from a single treatment interruption
17 December 2000. Related: Conference reports, Antiretrovirals.
A review of new anti-HIV drugs in development
17 December 2000. Related: Conference reports, Antiretrovirals.
Antiretroviral therapy in children, women and intravenous drug users
17 December 2000. Related: Conference reports, Women's health, Paediatric care.
Treatment of HIV+ subjects co-infected with hepatitis B or C: safety and efficacy comparison of ABT 378/r versus nelfinavir from a phase III blinded randomised clinical trial
17 December 2000. Related: Conference reports, Hepatitis coinfection.
Interferon-alpha and ribavarin therapy for hepatitis C in HIV coinfected patients
17 December 2000. Related: Conference reports, Hepatitis coinfection.
Lack of significant viral load alterations of hepatitis B virus (HBV) and hepatitis C virus (HCV) during treatment with interleukin-2 and HAART
17 December 2000. Related: Conference reports, Hepatitis coinfection.
Child protection issues around starting efavirenz in a mother on maintenance methadone
17 December 2000. Related: Conference reports.
Structured treatment interruptions
17 December 2000. Related: Conference reports, Treatment strategies.
Adherence and HAART: unique approaches to evaluating and improving adherence discussed
17 December 2000. Related: Conference reports, Antiretrovirals.
Importance of intensive adherence support for people with HIV-related neurological symptoms
17 December 2000. Related: Antiretrovirals.
Reports on lipodystrophy and metabolic complications
17 December 2000. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Opportunistic infections in the HAART era
17 December 2000. Related: Conference reports, Coinfections and complications.
FDA meeting on approving immune therapies: background and comment
17 December 2000. Related: Other news.
Adverse effects of antiretroviral therapy
17 December 2000. Related: Side effects.
Antiretrovirals do not independently affect T-cell count in HIV negative subjects
17 December 2000. Related: Basic science and immunology.
Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells
17 December 2000. Related: Basic science and immunology.
HLA-DR integrates with HIV-1 at chronic disease stage, may raise infectivity
17 December 2000. Related: Basic science and immunology.
Women initiate highly active antiretroviral therapy later than men
17 December 2000. Related: Women's health.
Efavirenz side effects become long-term for over one in three
17 December 2000. Related: Antiretrovirals, Side effects.
ABT-378/r oral formulation available in UK
17 December 2000. Related: Antiretrovirals.
Trimeris, Roche to begin phase III pivotal trials of T-20 HIV fusion inhibitor
17 December 2000. Related: Antiretrovirals.
Association of vitamin A deficiency With cervical squamous intraepithelial lesions in HIV-positive women
17 December 2000. Related: Women's health.
HIV seroprevalence by anonymous testing in patients with mycobacterium tuberculosis and in tuberculosis contacts
17 December 2000. Related: Other news.
HIV-1 Immunogen fails to extend HIV progression-free survival
17 December 2000. Related: Other news.
Immune Response Corporation tried to block report on failure of Remune
17 December 2000. Related: Vaccines and microbicides.
AIDS-related lymphoma
17 December 2000. Related: On the web.
Volume 1 Number 8 November / December 2000 PDF
1 December 2000. Related: PDFs.
2nd International Workshop on Adverse Drug Reactions and Lipodystrophy, Toronto, Canada, 13-15 September 2000
17 October 2000. Related: Conference reports.
Lipodystrophy: the current state of play
17 October 2000. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Metabolic effects – bone density and avascular necrosis
17 October 2000. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Lipoatrophy and facial wasting
17 October 2000. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Lactic acidosis
17 October 2000. Related: Conference reports, Side effects.
Lipodystrophy and metabolic changes in children
17 October 2000. Related: Conference reports, Paediatric care.
40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 September 2000
17 October 2000. Related: Conference reports.
Mitochondrial toxicity reports
17 October 2000. Related: Conference reports, Side effects.
Treatment interruption and salvage therapy
17 October 2000. Related: Conference reports, Drug resistance.
Are gender-related differences in viral load present in infants and children?
17 October 2000. Related: Conference reports, Paediatric care.
Immune reconstitution in children treated with HAART is independent of age
17 October 2000. Related: Conference reports, Paediatric care.
Pharmacokinetics in children and infants
17 October 2000. Related: Conference reports, Paediatric care.
Opportunistic illness and viral hepatitis co-infection
17 October 2000. Related: Conference reports, Coinfections and complications, Hepatitis coinfection.
United States FDA approves Kaletra for HIV infection
17 October 2000. Related: Antiretrovirals.
Study shows immune system can control HIV: early antiviral treatment primes the immune system to suppress viral levels without drugs
17 October 2000. Related: Treatment strategies, Basic science and immunology.
Enhancement of HIV type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption
17 October 2000. Related: Basic science and immunology.
Human IL-12 may augment HIV-specific immunity in HIV-positive patients
17 October 2000. Related: Treatment strategies.
United Kingdom authorities clear AIDS vaccine for human testing
17 October 2000. Related: Vaccines and microbicides.
Highly active antiretroviral therapy should continue even if immune restoration syndrome develops
17 October 2000. Related: Coinfections and complications.
Crystalluria common in HIV-positive patients using indinavir
17 October 2000. Related: Side effects.
Volume 1 Number 7 October 2000 PDF
1 October 2000. Related: PDFs.
Abacavir hypersensitivity cases following an interruption of therapy
16 September 2000. Related: Treatment alerts.
Videx EC (ddI, didanosine) – food restrictions
16 September 2000. Related: Antiretrovirals.
Structured treatment interruptions and treatment intensification
16 September 2000. Related: Treatment strategies.
Importance of protease inhibitor plasma levels in patients treated with genotypic-guided therapy
16 September 2000. Related: Antiretrovirals.
Scrub typhus: infection reduces viral load in some patients
16 September 2000. Related: Other news.
Duration of incubation affects subsequent rate of HIV disease progression
16 September 2000. Related: Basic science and immunology.
Population of HIV-targeted CD8 cells fluctuates with viral load during chronic infection
16 September 2000. Related: Basic science and immunology.
Murabutide inhibits HIV replication in macrophages and dendritic cells
16 September 2000. Related: Vaccines and microbicides.
Adverse effects of perinatal zidovudine exposure on HIV-infected infants
16 September 2000. Related: Paediatric care.
Early cognitive and motor developmental delays in HIV-infected infants
16 September 2000. Related: Paediatric care.
Topical cidofovir clears severe molluscum contagiosum in children with AIDS
16 September 2000. Related: Paediatric care, Coinfections and complications.